Patient portrayal

Patient portrayal.

LIBTAYO in combination with chemotherapy compared with chemotherapy alone

LIBTAYO was studied in a clinical trial that compared adult patients with advanced NSCLC who received LIBTAYO in combination with chemotherapy with those who received chemotherapy alone.

The study was designed to include adult patients regardless of their PD-L1 biomarker level and if they did not have abnormal EGFR, ALK, or ROS1 genes.

A total of
466 patients
were included in the study

312 patients were given LIBTAYO 350 mg every 3 weeks + chemotherapy containing platinum

154 patients were given chemotherapy containing platinum

As a first treatment, LIBTAYO in combination with chemotherapy helped patients live longer compared with chemotherapy alone

Median overall survival (OS)*

AT 21.9 MONTHS
half of the patients taking
LIBTAYO + chemotherapy
(156 out of 312 patients)
were alive
VS
AT 13.0 MONTHS
half of the patients taking
chemotherapy alone
(77 out of 154 patients)
were alive

*Median overall survival (OS) is the time in a trial—expressed in months or years—when half of the patients are still living.

As of June 2021, more patients were alive with LIBTAYO in combination with chemotherapy compared with chemotherapy alone.

180 out of 312
patients (58%) with LIBTAYO + chemotherapy
VS
72 out of 154
patients (47%) with chemotherapy alone

Patients were enrolled on an ongoing basis between June 17, 2019, and September 30, 2020. Patients were treated with LIBTAYO in combination with chemotherapy for an average of 38.5 weeks. The study is still ongoing, and patients will be followed up with for up to 3 years.

LIBTAYO in combination with chemotherapy reduced the chance of advanced NSCLC progressing compared with chemotherapy alone

LIBTAYO in combination with chemotherapy reduced the risk of cancer spreading, growing, or getting worse by 44% compared with chemotherapy alone.

Median progression-free survival (PFS)

AT 8.2 MONTHS
half of the patients taking
LIBTAYO + chemotherapy were alive
without their cancer spreading,
growing, or getting worse
VS
AT 5.0 MONTHS
half of the patients taking
chemotherapy alone were alive
without their cancer spreading,
growing, or getting worse

Median progression-survival (PFS) is the time in a trial—expressed in months or years—when half of the patients are still living without their cancer spreading, growing, or getting worse.

As of June 2021, advanced NSCLC had not progressed in more patients taking LIBTAYO in combination with chemotherapy compared with chemotherapy alone.§

108 out of 312
patients (35%) with
LIBTAYO + chemotherapy
VS
32 out of 154
patients (21%) with
chemotherapy alone§

§Patients were enrolled on an ongoing basis between June 17, 2019, and September 30, 2020. Patients were treated with LIBTAYO in combination with chemotherapy for an average of 38.5 weeks. The study is still ongoing, and patients will be followed up with for up to 3 years.

Individual results may vary.

Review the most common side effects of LIBTAYO in combination with chemotherapy.

See side effects from the study